Abstract
The K65R mutation in HIV-1 reverse transcriptase is associated with reduced susceptibility to abacavir and tenofovir. We established its prevalence within a large clinical database, and investigated correlations with other resistance-associated mutations and antiretroviral history. The presence of K65R is associated with previous abacavir use. Although rare, it is preferentially selected within non-thymidine analogue-containing regimens, compared with concurrent zidovudine or stavudine use, which is associated with thymidine analogue mutations. Both genetic routes may compromise abacavir and tenofovir activity.
MeSH terms
-
Adenine / analogs & derivatives*
-
Adenine / pharmacology*
-
Adenine / therapeutic use
-
Anti-HIV Agents / pharmacology*
-
Anti-HIV Agents / therapeutic use
-
Databases, Factual
-
Dideoxynucleosides / pharmacology
-
Dideoxynucleosides / therapeutic use
-
Drug Resistance, Viral / genetics
-
Drug Therapy, Combination
-
HIV Infections / drug therapy
-
HIV Infections / epidemiology*
-
HIV Infections / virology
-
HIV Reverse Transcriptase / genetics*
-
HIV-1 / enzymology
-
HIV-1 / genetics
-
Humans
-
Microbial Sensitivity Tests / methods
-
Mutation*
-
Organophosphonates*
-
Organophosphorus Compounds / pharmacology*
-
Organophosphorus Compounds / therapeutic use
-
Prevalence
-
Reverse Transcriptase Inhibitors / pharmacology*
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Tenofovir
Substances
-
Anti-HIV Agents
-
Dideoxynucleosides
-
Organophosphonates
-
Organophosphorus Compounds
-
Reverse Transcriptase Inhibitors
-
Tenofovir
-
HIV Reverse Transcriptase
-
Adenine
-
abacavir